Vaccinia Virus (VACV) & Orthopoxvirus Research Reagents — Antibodies & Recombinant Proteins

Vaccinia virus (VACV) is a large, enveloped, double-stranded DNA orthopoxvirus (~190 kb genome) that serves as the prototypic member of the Orthopoxvirus genus and is the basis for all smallpox vaccines. VACV is widely used as a model system for poxvirus biology, oncolytic virotherapy, and recombinant vaccine vector development. The virion produces two infectious forms — intracellular mature virus (IMV/MV) and extracellular enveloped virus (EEV/EV) — each displaying distinct surface antigens. Key MV surface targets include L1R, A27L, D8L, and H3L, while EV-specific targets include A33R and B5R. Antibodies targeting both forms are required for complete neutralization, making VACV antigen panels essential for vaccine efficacy studies and therapeutic antibody development against orthopoxviruses including mpox (monkeypox) and cowpox.

Research Use OnlyNot for diagnostic or therapeutic use.

abinScience offers orthopoxvirus reagents covering VACV, cowpox/CPXV, and myxoma virus — including recombinant neutralizing antibodies against all major MV and EV surface antigens (A27L, L1R, D8L, H3L, A33R, B5R), recombinant proteins, and polyclonal detection antibodies. Manufactured by AtaGenix Laboratories (ISO 9001 & ISO 13485). For mpox/monkeypox-specific reagents, see our dedicated MPXV page.

VACV — MV Surface Antigens (IMV Targets)

A27L
A27L is a homotrimeric MV surface protein that mediates GAG-dependent cell attachment and is one of the most immunogenic VACV antigens. Anti-A27 antibodies are a major component of vaccine-induced neutralizing immunity. Available: 6 recombinant antibody clones — 8E3 (VK519013), 1G6 (VK519023), 186# (VK519033), 188# (VK519043), 203# (VK519053), and IgA clone SAA2663 (VK415203); recombinant protein A27L GST-His (VK415032).

L1R
L1R is an essential myristoylated MV membrane protein required for virus entry and a target for potent neutralizing antibodies. Available: recombinant antibody clones 7D11 (VK725013) and M12B9 (VK725023) (both well-characterized MV-neutralizing clones), plus additional format variants (VK725033, VK725043); recombinant L1R proteins: C-His (VK785031) and N-His (VK785022).

D8L
D8L is an MV surface protein that binds chondroitin sulfate on host cells. Available: recombinant antibody clone LA5 (VK709013) in multiple format variants (VK709023, VK709033, VK709043); recombinant protein D8L N-His (VK709012).

H3L
H3L (Ag35) is an abundant MV surface glycoprotein that binds heparan sulfate. Available: recombinant antibody clone B9 (VK440013) and format variant VK440023; recombinant proteins VK814012 and VK814022 (both N-His tagged).

VACV — EV Surface Antigens (EEV Targets)

A33R
A33R is an EV-specific glycoprotein required for efficient virus release and long-range dissemination. Anti-A33R antibodies limit EV spread and are a component of multi-target orthopoxvirus therapeutics. Available: recombinant antibody clone A27D7 (VK465013) and format variant VK465023; recombinant VACV A33R protein GST-His (VK465012); ectromelia virus A33R protein His (VK759012) and anti-ECTV A33R pAb (VK759014).

B5R
B5R is an EV-specific complement control protein that protects EV from complement-mediated neutralization. Available: recombinant antibodies SAA0315 (VK444013) and 8AH8AL (VK444023); recombinant protein B5R N-His (VK444012).

VACV — Other Viral Proteins

Other VACV Proteins
Additional VACV targets include:
• A28L (entry/fusion complex) — polyclonal antibody (VK428014)
• L4R/VP8 (major core protein, DNA binding) — protein N-His (VK005012) and pAb (VK005014)
• F13L (palmitoylated EV membrane protein) — protein C-His (VK455022)
• I3L (ssDNA-binding protein, replication) — protein N-His (VK136012) and pAb (VK136014)
• E9L (DNA polymerase, drug target for cidofovir/brincidofovir) — protein N-Strep (VK135011)

Related Orthopoxviruses: Cowpox (CPXV) & Myxoma Virus

Cowpox Virus (CPXV)
CPXV has the largest genome among orthopoxviruses and encodes unique immunomodulatory proteins not found in VACV or MPXV. Available: recombinant proteins and polyclonal antibodies for CPXV-specific targets — CPXV187 (VK065012), CPXV203 (VK066012), CPXV208 (VK067012), CrmD (VK068012) (TNF receptor homolog, immune evasion), and vCCI (VK069012) (chemokine-binding protein). Each protein paired with a polyclonal detection antibody.

Myxoma Virus (MPV15)
Myxoma virus is a leporipoxvirus being developed as an oncolytic virotherapy agent. Available: recombinant proteins and polyclonal antibodies for key myxoma structural proteins — fusion glycoprotein F0 (VK010012), matrix protein (VK010032), M2-1 (VK010042), NS2 (VK010052), and NS1 (VK010062). Each paired with a polyclonal antibody.

Frequently Asked Questions

What is the difference between your VACV and MPXV reagent pages?
This page covers VACV-specific antigens (used in vaccine vector studies, oncolytic virus research, and smallpox biology), plus related orthopoxviruses CPXV and myxoma. Our MPXV page focuses on monkeypox-specific antigens (A29L, A35R, B6R, E8L, M1R) with 141 dedicated products. Some targets are homologous — VACV A27L = MPXV A29L, VACV A33R = MPXV A35R — so cross-reactivity is expected for certain antibodies.

Which antibodies neutralize both MV and EV forms?
Complete VACV neutralization requires targeting both viral forms. For MV: combine anti-A27L (8E3) + anti-L1R (7D11). For EV: add anti-A33R (A27D7) + anti-B5R (SAA0315). This four-antibody combination covers the key neutralizing determinants on both forms.

Do you have VACV-based recombinant vaccine vector tools?
We provide key VACV structural proteins (L4R/VP8, F13L, E9L, I3L) and their corresponding antibodies for monitoring recombinant VACV vector expression, characterizing viral particles, and quality control of VACV-vectored vaccines. Contact us for custom antigen and antibody production.

Related Poxvirus Reagents

Explore reagents for related poxviruses:

Mpox / MPXV Vaccinia (VACV) ✓ Lumpy skin disease (LSDV)